Cargando…

Comparative Effectiveness of Remestemcel-L-rknd versus Ruxolitinib in Pediatric Patients with Steroid-Refractory Acute Graft-Versus-Host Disease using Simulated Treatment Comparisons

Background: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) can be a lifesaving treatment for hematologic malignancies, but acute graft-versus-host-disease (aGVHD) is a potentially deadly adverse effect experienced by up to half of allo-HSCT recipients. Inadequate response to steroid...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tremblay, Gabriel, Tomaras, Dimitrios, Strati, Eric, Forsythe, Anna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Columbia Data Analytics, LLC 2021
Materias:	Hematology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7983491/ https://www.ncbi.nlm.nih.gov/pubmed/33768123 http://dx.doi.org/10.36469/jheor.2021.19008

Ejemplares similares

Study 275: Updated Expanded Access Program for Remestemcel-L in Steroid-Refractory Acute Graft-versus-Host Disease in Children
por: Kurtzberg, Joanne, et al.
Publicado: (2020)

Economic burden of acute steroid-refractory graft-versus-host disease in commercially insured pediatric patients
por: Grabner, Michael, et al.
Publicado: (2021)

Combination of bortezomib plus ruxolitinib in steroid-refractory chronic graft-versus-host disease
por: Kaloyannidis, Panayotis, et al.
Publicado: (2018)

Efficacy and safety of ruxolitinib in steroid-refractory graft-versus-host disease: A meta-analysis
por: Fan, Shuang, et al.
Publicado: (2022)

Efficiency and Toxicity of Ruxolitinib as a Salvage Treatment for Steroid-Refractory Chronic Graft-Versus-Host Disease
por: Wang, Dong, et al.
Publicado: (2021)

Recent FDA Approvals in the Treatment of Graft-Versus-Host Disease
por: Martini, Dylan J, et al.
Publicado: (2022)

Ruxolitinib for Treatment of Steroid-Refractory Graft-versus-Host Disease: Real-World Data from Chinese Patients
por: Wei, Cong, et al.
Publicado: (2021)

Effect of ruxolitinib on the oral mucosa of patients with steroid-refractory chronic Graft-versus-Host disease and oral involvement
por: Kaurinovic, Martina, et al.
Publicado: (2022)

The development of graft-versus-host disease prophylaxis
por: Cutler, Corey
Publicado: (2023)

Physicochemical Stability Study of Oral Suspension Containing Ruxolitinib in Children with Steroid-Refractory Acute Graft-Versus-Host Disease
por: Hinterlang, Mélanie, et al.
Publicado: (2022)

Real-world experience with ruxolitinib for steroid-refractory acute graft-versus-host disease: a single center experience
por: Spałek, Adrianna, et al.
Publicado: (2022)

Ruxolitinib in steroid refractory graft-vs.-host disease: a case report
por: Maffini, Enrico, et al.
Publicado: (2016)

Ruxolitinib for Therapy of Graft-versus-Host Disease
por: Neumann, Thomas, et al.
Publicado: (2019)

Efficacy of ESHAP versus ICE plus dexamethasone (DICE) as salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma
por: Boonlerd, Pattamaporn, et al.
Publicado: (2023)

Graft-versus-host disease in allogeneic transplantation: the good and the bad
por: Kröger, Nicolaus-Martin
Publicado: (2022)

Palatal superficial mucoceles associated with chronic graft-versus-host disease
por: Masri, Bilal Al, et al.
Publicado: (2023)

Efficacy and safety of ruxolitinib for steroid-refractory graft-versus-host disease: Systematic review and meta-analysis of randomised and non-randomised studies
por: Zhang, Meng-yun, et al.
Publicado: (2022)

Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study
por: Escamilla Gómez, Virginia, et al.
Publicado: (2019)

Murine Models of Steroid Refractory Graft-versus-Host Disease
por: Toubai, Tomomi, et al.
Publicado: (2018)

A cost-effectiveness analysis of ruxolitinib versus best alternative therapy for patients with steroid-refractory chronic graft-versus-host disease aged > 12 years in Singapore
por: Ong, Jian Chun Matthew, et al.
Publicado: (2023)

Intramesenteric Steroid Treatment for Steroid- Refractory Gastrointestinal Graft Versus Host Disease
por: Bilgin, Aynur Uğur, et al.
Publicado: (2012)

Durable discontinuation of systemic therapy in patients affected by chronic graft-versus-host disease
por: Chen, George L., et al.
Publicado: (2022)

Experimental Pharmaceuticals for Steroid-Refractory Acute Graft-versus-Host Disease
por: Abedin, Sameem, et al.
Publicado: (2020)

Compassionate use of ruxolitinib in acute and chronic graft versus host disease refractory both to corticosteroids and extracorporeal photopheresis
por: Sarmiento Maldonado, Mauricio, et al.
Publicado: (2017)

Treatment and unmet needs in steroid-refractory acute graft-versus-host disease
por: Malard, Florent, et al.
Publicado: (2020)

Fecal microbiota transplantation for steroid-refractory gastrointestinal graft-versus-host disease
por: Kim, Hyun Min, et al.
Publicado: (2023)

S245: RUXOLITINIB IN PEDIATRIC PATIENTS WITH TREATMENT-NAIVE OR STEROID-REFRACTORY CHRONIC GRAFT VERSUS HOST DISEASE: PRIMARY FINDINGS FROM THE PHASE II REACH5 STUDY
por: Locatelli, Franco, et al.
Publicado: (2023)

Evaluation of Ruxolitinib for Steroid-Refractory Chronic Graft-vs-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
por: Wu, Hengwei, et al.
Publicado: (2021)

Zinc Deficiency-induced Hypogeusia in a Patient with Refractory Iron-deficiency Anemia: A Case Report
por: Gooding, Alex J, et al.
Publicado: (2019)

Comprehensive meta-analysis of anti-BCMA chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma
por: Zhang, Lina, et al.
Publicado: (2021)

Late Onset and Protracted Course of Steroid Refractory Chronic Graft-versus-Host Disease
por: Gunes, Gursel, et al.
Publicado: (2015)

Steroid-refractory chronic graft-versus-host disease: treatment options and patient management
por: Wolff, Daniel, et al.
Publicado: (2021)

Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)
por: von Bubnoff, Nikolas, et al.
Publicado: (2018)

Sirolimus is effective for primary refractory/relapsed warm autoimmune haemolytic anaemia/Evans syndrome: a retrospective single-center study
por: Zhang, Zhuxin, et al.
Publicado: (2023)

Combined treatment of graft versus host disease using donor regulatory T cells and ruxolitinib
por: Rodríguez-Gil, Alfonso, et al.
Publicado: (2022)

Blinatumomab as salvage therapy in patients with relapsed/refractory B-ALL who have failed/progressed after anti-CD19-CAR T therapy
por: Qi, Yao, et al.
Publicado: (2023)

Avatrombopag, a promising novel thrombopoietin receptor agonist for refractory/relapsed/intolerant non-severe aplastic anemia: a phase 2 single-arm clinical trial
por: Wan, Ziqi, et al.
Publicado: (2023)

A Phase 3, Single-Arm, Prospective Study of Remestemcel-L, Ex Vivo Culture-Expanded Adult Human Mesenchymal Stromal Cells for the Treatment of Pediatric Patients Who Failed to Respond to Steroid Treatment for Acute Graft-versus-Host Disease
por: Kurtzberg, Joanne, et al.
Publicado: (2020)

Etanercept for steroid-refractory acute graft-versus-host disease: A single center experience
por: De Jong, Cornelis N., et al.
Publicado: (2017)

Umbilical Cord Mesenchymal Stromal Cells for Steroid-Refractory Acute Graft-versus-Host Disease
por: Donadel, Camila Derminio, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_t633olglin01br50u9hhi0muvj